cystine dihydrochloride | 13059-63-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: cystine dihydrochloride
• 英文别名: (2R,2R)-3,3-Disulfanediylbis(2-aminopropanoic acid) xHCl；2-amino-3-[(2-amino-2-carboxyethyl)disulfanyl]propanoic acid;hydron;chloride
• CAS: 13059-63-7
• 化学式: C₆H₁₂N₂O₄S₂*2ClH
• 分子量: 313.226
• InChiKey: IOCJWNPYGRVHLN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.39
• 重原子数：
  15
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  177
• 氢给体数：
  5
• 氢受体数：
  8

安全信息

• 海关编码：
  2930909090

SDS

---

Section I.Chemical Product and Company Identification
Chemical Name L-(-)-Cystine Dihydrochloride
Portland OR
Synonym L-Cystine, radical ion(1+), dihydrochloride (9CI)
Chemical Formula C6H12N2O4S2•2HCl
13059-63-7
CAS Number

---

Section II. Composition and Information on Ingredients
Chemical Name CAS Number Percent (%) TLV/PEL Toxicology Data
L-(-)-Cystine Dihydrochloride 13059-63-7 Min. 98.0 Not available. Not available.
(HPLC,T)

---

Section III. Hazards Identification
No specific information is available in our data base regarding the toxic effects of this material for humans. However,
Acute Health Effects
exposure to any chemical should be kept to a minimum. Skin and eye contact may result in irritation. May be harmful if
inhaled or ingested. Always follow safe industrial hygiene practices and wear proper protective equipment when handling
this compound.
Follow safe industrial hygiene practices and always wear proper protective equipment when handling this compound.
CARCINOGENIC EFFECTS : Not available.
Chronic Health Effects
MUTAGENIC EFFECTS : Not available.
TERATOGENIC EFFECTS : Not available.
DEVELOPMENTAL TOXICITY: Not available.
Repeated or prolonged exposure to this compound is not known to aggravate existing medical conditions.

---

Section IV. First Aid Measures
Check for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at least 15
Eye Contact
minutes. Get medical attention.
In case of contact, immediately flush skin with plenty of water. Remove contaminated clothing and shoes. Wash clothing
Skin Contact
before reuse. Thoroughly clean shoes before reuse. Get medical attention.
Inhalation If the victim is not breathing, perform mouth-to-mouth resuscitation. Loosen tight clothing such as a collar, tie, belt or
waistband. If breathing is difficult, oxygen can be administered. Seek medical attention if respiration problems do not
improve.
Ingestion INDUCE VOMITING by sticking finger in throat. Lower the head so that the vomit will not reenter the mouth and throat.
Loosen tight clothing such as a collar, tie, belt or waistband. If the victim is not breathing, perform mouth-to-mouth
resuscitation. Examine the lips and mouth to ascertain whether the tissues are damaged, a possible indication that the toxic
material was ingested; the absence of such signs, however, is not conclusive.

---

Section V. Fire and Explosion Data
Not available.
May be combustible at high temperature. Auto-Ignition
Flammability
Flammable Limits Not available.
Flash Points Not available.
Combustion Products These products are toxic carbon oxides (CO, CO2), nitrogen oxides (NO, NO2), sulfur oxides (SO2, SO3...). halogenated
compounds.
WARNING: Highly toxic HCl gas is produced during combustion.
Fire Hazards
Not available.
Risks of explosion of the product in presence of mechanical impact: Not available.
Explosion Hazards
Risks of explosion of the product in presence of static discharge: Not available.
Fire Fighting Media SMALL FIRE: Use DRY chemical powder.
LARGE FIRE: Use water spray, fog or foam. DO NOT use water jet.
and Instructions
Consult with local fire authorities before attempting large scale fire-fighting operations.
Continued on Next Page
L-(-)-Cystine Dihydrochloride

---

Section VI. Accidental Release Measures
Spill Cleanup Use a shovel to put the material into a convenient waste disposal container. Finish cleaning the spill by rinsing any
contaminated surfaces with copious amounts of water. Consult federal, state, and/or local authorities for assistance on
Instructions
disposal.

---

Section VII. Handling and Storage
Handling and Storage Keep away from heat. Mechanical exhaust required. When not in use, tightly seal the container and store in a dry, cool
place. Avoid excessive heat and light. Do not breathe dust.
Information
Always store away from incompatible compounds such as oxidizing agents.

---

Section VIII. Exposure Controls/Personal Protection
Use process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels below recommended
Engineering Controls
exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to airborne contaminants
below the exposure limit.
Splash goggles. Lab coat. Dust respirator. Boots. Gloves. Suggested protective clothing might not be sufficient; consult a
Personal Protection
specialist BEFORE handling this product. Be sure to use a MSHA/NIOSH approved respirator or equivalent.
Exposure Limits Not available.

---

Section IX. Physical and Chemical Properties
Solid. (White crystalline powder.) Solubility
Physical state @ 20°C Not available.
Not available.
Specific Gravity
313.22
Molecular Weight Partition Coefficient Not available.
Boiling Point Not available. Vapor Pressure Not applicable.
Not available. Not available.
Melting Point Vapor Density
Not available. Volatility Not available.
Refractive Index
Not available.
Critical Temperature Not available. Odor
Viscosity Not available. Taste Not available.

---

Section X. Stability and Reactivity Data
Stability

---

This material is stable if stored under proper conditions. (See Section VII for instructions)
Conditions of Instability Avoid excessive heat and light.
Incompatibilities
Reactive with oxidizing agents.

---

Section XI. Toxicological Information
Not available.
RTECS Number
Routes of Exposure Eye Contact. Ingestion. Inhalation.
Not available.
Toxicity Data
Chronic Toxic Effects CARCINOGENIC EFFECTS : Not available.
MUTAGENIC EFFECTS : Not available.
TERATOGENIC EFFECTS : Not available.
DEVELOPMENTAL TOXICITY: Not available.
Repeated or prolonged exposure to this compound is not known to aggravate existing medical conditions.
Acute Toxic Effects No specific information is available in our data base regarding the toxic effects of this material for humans. However,
exposure to any chemical should be kept to a minimum. Skin and eye contact may result in irritation. May be harmful if
inhaled or ingested. Always follow safe industrial hygiene practices and wear proper protective equipment when handling this
compound.
Follow safe industrial hygiene practices and always wear proper protective equipment when handling this compound.

---

Section XII. Ecological Information
Not available.
Ecotoxicity
Not available.
Environmental Fate
Continued on Next Page
L-(-)-Cystine Dihydrochloride

---

Section XIII. Disposal Considerations
Waste Disposal Recycle to process, if possible. Consult your local regional authorities. You may be able to dissolve or mix material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber system. Observe all
federal, state and local regulations when disposing of the substance.

---

Section XIV. Transport Information
Not a DOT controlled material (United States).
DOT Classification
PIN Number Not applicable.
Proper Shipping Name Not applicable.
Packing Group (PG) Not applicable.
DOT Pictograms

---

Section XV. Other Regulatory Information and Pictograms
TSCA Chemical Inventory This product is NOT on the EPA Toxic Substances Control Act (TSCA) inventory. The following notices are required by 40
CFR 720.36 (C) for those products not on the inventory list:
(EPA)
(i) These products are supplied solely for use in research and development by or under the supervision of a technically
qualified individual as defined in 40 CFR 720.0 et sec.
(ii) The health risks of these products have not been fully determined. Any information that is or becomes available will be
supplied on an MSDS sheet.
WHMIS Classification Not controlled under WHMIS (Canada).
(Canada)
EINECS Number (EEC) Not available.
EEC Risk Statements Not available.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

文献信息

• Alkylated fluorochemical oligomers and use thereof in the treatment of fibrous substrates
  申请人：——

  公开号：US20040024262A1

  公开（公告）日：2004-02-05

  This invention provides a method of treating fibrous substrates, such as leather, by contacting the substrate with a fluorochemical compound comprising: a fluorochemical oligomeric portion comprising an aliphatic backbone with a plurality of pendant fluoroaliphatic groups, each fluoroaliphatic group having a fully fluorinated terminal group and each independently linked to a carbon atom of the aliphatic backbone through an organic linking group; an aliphatic moiety; and a linking group which links the fluorochemical oligomeric portion to the aliphatic moiety. The fluorochemical compounds provide desirable oil, water and stain repellency to fibrous substrates.

  这项发明提供了一种处理纤维基质（如皮革）的方法，包括将基质与含有氟化合物接触，该氟化合物包括：含有脂肪族骨架和多个挂链氟脂肪基团的氟化合物寡聚物部分，每个氟脂肪基团具有全氟化的末端基团，并且每个通过有机连接基团独立连接到脂肪族骨架的碳原子上；脂肪基团；以及将氟化合物寡聚物部分连接到脂肪基团的连接基团。这些氟化合物为纤维基质提供了理想的油、水和污渍防护性能。
• [EN] POLYAMIDE MICROCAPSULES<br/>[FR] MICROCAPSULES DE POLYAMIDE
  申请人：FIRMENICH & CIE

  公开号：WO2021254931A1

  公开（公告）日：2021-12-23

  The present invention relates to polyamide microcapsules. A process for the preparation of polyamide microcapsules is also an object of the invention. Perfuming compositions and consumer products comprising said microcapsules, in particular perfumed consumer products in the form of home care or personal care products, are also part of the invention.

  本发明涉及聚酰胺微胶囊。制备聚酰胺微胶囊的方法也是本发明的目标。包括这些微胶囊的香料组合物和消费品，特别是家居护理或个人护理产品的香气消费品，也是本发明的一部分。
• Sustained release preparation
  申请人：TEIJIN LIMITED

  公开号：EP0187703A2

  公开（公告）日：1986-07-16

  A sustained release preparation comprising: (a) chitin, chitosan, or a mixture thereof (b) anionic polymer compounds such as those having a carboxyl group, a sulfonic acid group, or a group capable of providing the same, and (c) pharmaceutically active agents. This sustained release preparation can provide the desired sustained-release or dissolution of the pharmaceutically active agents in human organs irrespective of the acidity (i.e., pH conditions) therein.

  一种缓释制剂，包括：(a) 甲壳素、壳聚糖或它们的混合物；(b) 阴离子聚合物化合物，如具有羧基、磺酸基或能提供相同羧基、磺酸基的化合物；(c) 药物活性剂。 这种缓释制剂能在人体器官中提供所需的药物活性剂的缓释或溶解，而不受其中酸度（即 pH 值条件）的影响。
• Sustained-release pharmaceutical preparation
  申请人：TEIJIN LIMITED

  公开号：EP0207638A2

  公开（公告）日：1987-01-07

  A sustained release preparation comprising: (a) a non-anionic celllulose ether (b) a methoxyethylene-maleic anhydride copolymer or the hydrolyzate thereof, and (c) pharmaceutically active agents. This sustained release preparation can provide the desired sustained-release or dissolution of the pharmaceutically active agents in human organs irrespective of the acidity (j.e., pH conditions) therein.

  一种缓释制剂，包括 (a) 非阴离子纤维素醚 (b) 甲氧基乙烯-马来酸酐共聚物或其水解物，以及 (c) 药物活性剂。 这种缓释制剂可以在人体器官中提供所需的药物活性剂的缓释或溶解，而与其中的酸度（即 pH 值条件）无关。
• Patch and method for transdermal delivery of bupropion base
  申请人：Pierce Management, L.L.P.

  公开号：EP1051971A1

  公开（公告）日：2000-11-15

  The invention includes a patch and method for transdermal delivery of bupropion base. In the method of this invention, a patient is administered a bupropion base in an amount effective to alleviate withdrawal symptoms and to prevent or reduce craving of nicotine in said patient. Alternatively, an effective amount of bupropion base is delivered to alleviate depression in a patient or to treat obesity. A transdermal patch includes a bupropion base. The bupropion base can be mixed with an acceptable pharmaceutical carrier.

  本发明包括一种经皮给药安非他酮基的贴片和方法。在本发明的方法中，给病人服用有效量的安非他酮碱，以减轻戒断症状，防止或减少病人对尼古丁的渴求。或者，给病人服用有效量的安非他酮碱，以减轻病人的抑郁或治疗肥胖症。透皮贴剂包括安非他酮基。安非他酮碱可与可接受的药物载体混合。